| pubmed-article:15813849 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15813849 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:15813849 | lifeskim:mentions | umls-concept:C0008628 | lld:lifeskim |
| pubmed-article:15813849 | lifeskim:mentions | umls-concept:C1521970 | lld:lifeskim |
| pubmed-article:15813849 | lifeskim:mentions | umls-concept:C0220901 | lld:lifeskim |
| pubmed-article:15813849 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:15813849 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:15813849 | pubmed:dateCreated | 2005-4-7 | lld:pubmed |
| pubmed-article:15813849 | pubmed:abstractText | Del (9q) is a recurrent cytogenetic abnormality in acute myeloid leukaemia (AML). We report an analysis of 81 patients with del(9q) as a diagnostic karyotypic abnormality entered into the Medical Research Council AML trials 10, 11 and 12. Patients were divided into three groups: (i) Sole del (9q), 21 patients; (ii) Del(9q) in association with t(8;21), 29 patients; (iii) Del(9q) in association with other cytogenetic abnormalities, 31 patients. Sole del(9q) was associated with a characteristic bone marrow phenotype at diagnosis: a single Auer rod was found in all cases examined. There was also an association with erythroid dysplasia (74%) and granylocytic lineage vacuolation (90%). The incidence of all three of these features was significantly higher (P < 0.05) in the sole del(9q) group compared with control cases lacking del(9q). The overall survival (OS) of all 81 patients was compared with a control group of 1738 patients with normal cytogenetics entered in the same trials over the period of investigation. The 5-year OS for patients with del(9q) was 45%, compared with 35% for the control group (P = 0.09). Patients with del(9q) in association with t(8;21) had a 5-year OS of 75%, which was significantly better than the groups with either sole del(9q) (40%) and del(9q) with other abnormalities (26%; P = 0.008). Karyotyping indicated a common area of deletion in the region 9q21-22, which was present in 94% of cases. It is likely that the deletion of single or multiple tumour suppressor genes located in this region may underlie the pathogenesis of del (9q) AML. | lld:pubmed |
| pubmed-article:15813849 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15813849 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15813849 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15813849 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15813849 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15813849 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15813849 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:15813849 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:15813849 | pubmed:author | pubmed-author:HarrisonChris... | lld:pubmed |
| pubmed-article:15813849 | pubmed:author | pubmed-author:GoldstoneAnth... | lld:pubmed |
| pubmed-article:15813849 | pubmed:author | pubmed-author:SideLucyL | lld:pubmed |
| pubmed-article:15813849 | pubmed:author | pubmed-author:WalkerHelenH | lld:pubmed |
| pubmed-article:15813849 | pubmed:author | pubmed-author:WheatleyKeith... | lld:pubmed |
| pubmed-article:15813849 | pubmed:author | pubmed-author:BoultwoodJacq... | lld:pubmed |
| pubmed-article:15813849 | pubmed:author | pubmed-author:BurnettAlanA | lld:pubmed |
| pubmed-article:15813849 | pubmed:author | pubmed-author:KusecRajkoR | lld:pubmed |
| pubmed-article:15813849 | pubmed:author | pubmed-author:BuckGeorginaG | lld:pubmed |
| pubmed-article:15813849 | pubmed:author | pubmed-author:PeniketAndrew... | lld:pubmed |
| pubmed-article:15813849 | pubmed:author | pubmed-author:WainscoatJame... | lld:pubmed |
| pubmed-article:15813849 | pubmed:author | pubmed-author:DalySarahS | lld:pubmed |
| pubmed-article:15813849 | pubmed:author | pubmed-author:ChattersSteve... | lld:pubmed |
| pubmed-article:15813849 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15813849 | pubmed:volume | 129 | lld:pubmed |
| pubmed-article:15813849 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15813849 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15813849 | pubmed:pagination | 210-20 | lld:pubmed |
| pubmed-article:15813849 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:meshHeading | pubmed-meshheading:15813849... | lld:pubmed |
| pubmed-article:15813849 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15813849 | pubmed:articleTitle | Del (9q) AML: clinical and cytological characteristics and prognostic implications. | lld:pubmed |
| pubmed-article:15813849 | pubmed:affiliation | Leukaemia Research Fund Molecular Haematology Unit, John Radcliffe Hospital, Oxford, UK. andy.peniket@orh.nhs.uk | lld:pubmed |
| pubmed-article:15813849 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15813849 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15813849 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15813849 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15813849 | lld:pubmed |
